Patents older than age 65 represent 13 percent of the U.S. population, yet they receive more than 35 percent of all prescription drugs and disproportionately suffer adverse experiences from psychotropic medications. The critical gaps in our knowledge of appropriate pharmacotherapy for elders with psychiatric illness are exacerbated by the shortage of new investigators trained in geriatric clinical pharmacology. This K24 award addresses this important problem by supporting further career development for an established investigator in geriatric psychopharmacology and his mentoring of junior investigators in patient-oriented research. The overarching goal of this candidate's research program is to determine inter-individual pharmacokinetic and pharmacodynamic variables affecting treatment outcome as well as to specifically address the dearth of information regarding newer antidepressants and antipsychotics in elderly patients. The primary developmental goal during the proposed K24 award period is for the candidate to enhance his expertise in population pharmacokinetics using mixed-effects modeling. This builds on the current strengths of his research program, and represents a very significant enhancement by permitting more optimal utilization of sparse drug concentration data from clinical trials. The secondary developmental goal is for the candidate to deepen his knowledge of basic and quantitative genetics. Developmental activities will occur primarily in the context of the candidate's current R01 """"""""Continuation Pharmacotherapy for Agitation in Dementia"""""""". The goal of this study is to improve the treatment of non-cognitive symptoms of dementia in severely affected patients. This protocol will test if the highly selective serotonin reuptake inhibitor (SSRI) citalopram and the atypical antipsychotic risperidone are differentially effective in ameliorating behavioral symptoms and/or psychosis particularly during continuing pharmacotherapy upon discharge from a hospital setting. The candidate also proposes to enhance his skills as a mentor by working closely with experienced medical educators. He will recruit at least two new trainees per year through three Departmental training grants with which he is closely associated. Trainees will be medical students, residents, post-doctoral fellows and junior faculty. Particular emphasis will be given to increasing recruitment of under-represented minorities. The applicant will mentor trainees in analyses of existing data as well as design and implementation of clinical studies. Success in mentoring will be judged by trainee's productivity in peer-reviewed publications and competition for career development awards and research funding.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24MH065416-04
Application #
6886780
Study Section
Special Emphasis Panel (ZMH1-ITV-D (01))
Program Officer
Evans, Jovier D
Project Start
2002-05-01
Project End
2007-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
4
Fiscal Year
2005
Total Cost
$125,990
Indirect Cost
Name
University of Pittsburgh
Department
Psychiatry
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Sherer, Eric A; Sale, Mark E; Pollock, Bruce G et al. (2012) Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. J Pharmacokinet Pharmacodyn 39:393-414
Mah, Linda; Pollock, Bruce G (2010) Emotional processing deficits in late-life depression. Am J Geriatr Psychiatry 18:652-6
Wessels, Alette M; Pollock, Bruce G; Anyama, Norbert G et al. (2010) Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. J Clin Psychopharmacol 30:683-7
Franzen, Peter L; Buysse, Daniel J; Rabinovitz, Mordechai et al. (2010) Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Res 177:240-5
Dombrovski, Alexandre Y; Mulsant, Benoit H; Ferrell, Robert E et al. (2010) Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol 25:37-45
Jin, Yuyan; Pollock, Bruce G; Coley, Kim et al. (2010) Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol 50:73-80
Culo, Sandi; Mulsant, Benoit H; Rosen, Jules et al. (2010) Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord 24:360-4
Uchida, Hiroyuki; Mamo, David C; Mulsant, Benoit H et al. (2009) Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 70:397-405
Smith, Gwenn S; Reynolds 3rd, Charles F; Houck, Patricia R et al. (2009) Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: a randomized, placebo-controlled study. Psychiatry Res 171:1-9
Lotrich, Francis E; Ferrell, Robert E; Rabinovitz, Mordechai et al. (2009) Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 65:344-8

Showing the most recent 10 out of 59 publications